VERMOX
LOE ApproachingNDAORALTABLET, CHEWABLEPriority Review
Approved
Jun 1974
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 9h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VERMOX is an oral chewable tablet small-molecule anthelmintic approved in 1974 by Johnson & Johnson. The drug treats parasitic worm infections across multiple indications. Mechanism of action details are not specified in available data.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30/100), signaling potential team downsizing or transition focus.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on VERMOX offers limited career growth opportunity given LOE approaching status and zero linked job openings. This role suits professionals seeking to develop defensive commercial strategies or manage legacy product transitions rather than pursue growth-stage challenges.
Brand ManagerField Sales Representative
Worked on VERMOX at Johnson & Johnson? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.